Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
According to the recently published report 'Lysophosphatidic Acid Receptor 1 - Drugs In Development, 2022'; Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies.
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Lysophosphatidic acid receptor 1 is a G protein-coupled receptor that binds the lipid signaling molecule lysophosphatidic acid (LPA). Lysophosphatidic acid (LPA) receptor belongs to a group known as EDG receptors. EDG receptors mediate diverse biologic functions, including proliferation, platelet aggregation, and smooth muscle contraction, inhibition of neuroblastoma cell differentiation, chemotaxis, and tumor cell invasion.
The report 'Lysophosphatidic Acid Receptor 1 - Drugs In Development, 2022' outlays comprehensive information on the Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 6 and 1 respectively. Report covers products from therapy areas Respiratory, Gastrointestinal, Metabolic Disorders, Genito Urinary System And Sex Hormones, Immunology, Musculoskeletal Disorders and Toxicology which include indications Idiopathic Pulmonary Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Diabetic Nephropathy, Pulmonary Fibrosis, Diabetic Neuropathy, Diarrhea, Fibrosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Kidney Fibrosis, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and Systemic Sclerosis (Scleroderma).
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook